Recipharm and Medspray establish joint venture to exploit novel softmist technology

Resyca BV will provide a "unique offering" to the market — environmentally friendly, softmist spray nozzle technology for pharmaceutical applications.

Recipharm will invest EUR 15 million in return for 51% of the shares of Resyca.

Medspray will transfer its softmist intellectual property relating to pharmaceutical applications into Resyca. The technology is environmentally friendly and sustainable as it could potentially eliminate the need for propellants by delivering therapies deep into the lungs more effectively with lower doses as less ends up in the mouth and throat.

Commenting on the joint venture, Jean-François Hilaire, EVP Strategy and Global Integration, Recipharm AB, said: “ We are already seeing significant interest in such technologies and by combining Medspray’s knowhow in spray nozzle technology with Recipharm’s device and pharmaceutical expertise, we are confident we will provide a unique offering to the market.”

Resyca will operate development facilities in Munich, Germany and spray nozzles will be supplied exclusively from Medspray in the Netherlands.

It is envisaged that commercial supply of finished devices will be manufactured and supplied by other Recipharm affiliates including the specialist device manufacturing capabilities located in King’s Lynn, UK.

In addition, Recipharm will receive an exclusive licence to offer its customers the development and manufacturing of syringe-based devices using the softmist nozzle technology. Such devices will be marketed by Recipharm under the brand, Bespak by Recipharm.